SPR and BLI: Label-Free Methods for Antibody Binding Kinetics

Knowing that an antibody binds its target is only the beginning. Understanding how strongly it binds (affinity), how quickly it binds (association rate), and how slowly it releases (dissociation rate) is essential for selecting the best antibody for therapeutic development, diagnostic assay design, and quality control. Surface plasmon resonance (SPR) and biolayer interferometry (BLI) are the two leading label-free technologies for measuring these kinetic parameters in real time.

1. Why Binding Kinetics Matter

Two antibodies may have the same equilibrium dissociation constant (K_D) but very different kinetic profiles. One might bind quickly and release quickly (fast on, fast off); another might bind slowly but hold on tightly (slow on, slow off). These differences profoundly affect performance: a slow-off-rate antibody is better for therapeutic applications (longer target occupancy in vivo), while a fast-on-rate antibody may be preferred for rapid diagnostic assays. Kinetic data also reveals whether an antibody achieves its affinity through strong initial binding or through prolonged residence time — information that is invisible in endpoint assays like ELISA.

2. How SPR Works

In SPR, one binding partner (the "ligand," typically the antigen) is immobilized on a gold-coated sensor chip. The other partner (the "analyte," typically the antibody) flows over the chip surface in solution. When the analyte binds the ligand, the local refractive index at the chip surface changes, which shifts the angle of light reflection (the surface plasmon resonance angle). This shift is measured in real time as "resonance units" (RU) and plotted as a sensorgram: binding causes the signal to rise (association phase), and when analyte flow is replaced with buffer, the signal decreases as the complex dissociates (dissociation phase).

The association and dissociation curves are fitted to kinetic models (typically 1:1 Langmuir binding) to extract k_on (association rate constant), k_off (dissociation rate constant), and K_D = k_off/k_on.

3. How BLI Works

BLI uses disposable fiber-optic biosensor tips coated with a capture molecule (e.g., Protein A, anti-human IgG Fc, streptavidin, or Ni-NTA). The tip is dipped into a solution containing the binding partner. When molecules bind to the tip surface, they change the interference pattern of white light reflected from the tip, producing a wavelength shift measured in nanometers (nm). Like SPR, BLI generates real-time association and dissociation curves from which kinetic constants are derived.

The key mechanical difference: SPR uses a microfluidic flow system, while BLI uses a "dip-and-read" format where the sensor tip is physically moved between wells of a microplate. This makes BLI faster to set up, easier to use, and more tolerant of crude samples (cell culture supernatants, serum), though generally less sensitive than SPR for very slow off-rates.

4. Key Parameters: K_D, k_on, k_off

5. SPR vs. BLI: When to Use Which

Both platforms are widely used in recombinant antibody development workflows, from initial hit screening through lead optimization. VHH nanobodies, with their single-domain format, are particularly well-suited for BLI characterization due to their small size and simple binding kinetics.

6. Frequently Asked Questions

Q: Do I need purified antibody for SPR/BLI?

For SPR, purified antibody is strongly recommended because crude samples can cause non-specific binding and clog the microfluidic system. For BLI, crude samples (hybridoma supernatant, transfection conditioned medium) are acceptable for preliminary screening because the dip-and-read format is less sensitive to sample matrix effects. However, for precise kinetic determination, purified antibody is preferred on both platforms.

Q: What is epitope binning and how does it use SPR/BLI?

Epitope binning is a competition-based assay that determines whether two antibodies bind overlapping or distinct epitopes on the same target. In a typical BLI binning experiment: the target antigen is loaded onto a biosensor, saturated with Antibody A, and then dipped into a solution of Antibody B. If Antibody B binds (additional wavelength shift), the two antibodies recognize distinct epitopes ("different bins"). If Antibody B does not bind (no additional shift), they compete for the same epitope ("same bin"). BLI's parallel format makes it ideal for binning large panels of antibodies quickly. For more on how epitope location affects antibody function, see our Antibody Specificity and Validation guide.

Q: How does SPR/BLI differ from ELISA for measuring antibody affinity?

ELISA measures endpoint binding at equilibrium — it can estimate relative affinity but cannot provide kinetic rate constants (k_on, k_off). SPR and BLI measure binding in real time, providing both the equilibrium constant (K_D) and the individual rate constants. Additionally, SPR/BLI are label-free (no enzyme or fluorophore conjugation needed), eliminating the risk that labeling alters binding behavior. For rigorous affinity determination, SPR/BLI is the gold standard; ELISA is useful for initial screening but should not be used to report precise K_D values.

Q: Can I use abinScience proteins as antigens for SPR/BLI experiments?

Yes. abinScience recombinant proteins are widely used as antigens (ligands) for SPR and BLI kinetic studies. For amine coupling to SPR chips, use carrier-free proteins to avoid BSA interference. For BLI, His-tagged proteins can be captured directly on Ni-NTA biosensor tips, and biotinylated proteins on streptavidin tips. Over 100 abinScience antibody products include SPR-validated binding data on their datasheets. For best practices on reconstituting and handling recombinant proteins before loading, see our Recombinant Protein Handling Guide.

Q: Can I use research biosimilars as reference standards in SPR/BLI?

Yes. Research biosimilar antibodies are commonly used as positive control analytes in SPR/BLI experiments to benchmark novel antibody candidates against known therapeutic molecules. Because they share the same amino acid sequence as the originator drug, they provide a relevant kinetic reference point for K_D, k_on, and k_off comparison.

References

1. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using affinity biosensors. Anal Biochem. 2006;349(1):136-147. doi: 10.1016/j.ab.2005.09.034

2. Abdiche Y, Malashock D, Pinkerton A, Pons J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem. 2008;377(2):209-217. doi: 10.1016/j.ab.2008.03.035

3. Estep P, Reid F, Naber C, et al. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs. 2013;5(2):270-278. doi: 10.4161/mabs.23049

This article is provided for educational purposes only. For technical support, contact order@abinscience.com.